emc易倍官网入口Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Press Releases
  • Investors
  • Partnering
  • Careers arrow down
      < Back
    • Careers
    • emc易倍官网入口Careers
    • Working at Ipsen
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Canada
    <
    • Global EN FR
    • emc易倍官网入口Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • Brazil
    • emc易倍官网入口 Canada
    • United States
    • emc易倍官网入口 Mexico
    • Australia
    • emc易倍官网入口 China
    • Singapore
    • emc易倍官网入口 South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • emc易倍官网入口 Italy
    • emc易倍官网入口 Netherlands
    • Spain
    • emc易倍官网入口 Poland
    • Russia
    • Czech Republic
    • Romania
    • Hungary
    • Slovakia
    • emc易倍官网入口 Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Who We Are
    • emc易倍官网入口Leadership
    • Our History
  • Science
      < Back
    • Science
    • Areas of Focus
    • Products
    • Clinical Trials
    • R&D
    • emc易倍官网入口Grant Requests
    • Investigator Sponsored Studies
  • Sustainability
      < Back
    • emc易倍官网入口Sustainability
    • Sustainability
    • Environment
    • emc易倍官网入口People
    • Governance
    • emc易倍官网入口Charitable Contributions
  • Patients
  1. Home
  2. Press Releases

emc易倍官网入口

A comprehensive library of Ipsen media releases for investors and members of the press.

emc易倍官网入口

Topics

Period

recent search

Reset

Showing: 1 – 5 of 20 Press Releases

28 April 2025

28 April 2025

Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Health Canada approves IQIRVO? as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis

04 May 2022

04 May 2022

Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Health Canada approves Ipsen’s CABOMETYX? (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory or Ineligible Differentiated Thyroid Cancer

20 October 2021

20 October 2021

Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Health Canada approves Ipsen’s CABOMETYX? (cabozantinib) in combination with OPDIVO? (nivolumab) as a first-line treatment for adults with advanced or metastatic renal cell carcinoma

16 March 2021

16 March 2021

Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Health Canada Approves INCRELEX?, First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents

04 May 2020

04 May 2020

Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program

  • 1
  • 2
  • …
  • 4

IPN price

€168.10

 €2.10 (1.27%)

  • Investors
  • Partnering
  • Careers
  • Who We Are
  • Sustainability
  • emc易倍官网入口 Contact us
Ipsen logo
Linkedin Instagram Facebook Youtube
  • Terms of Use
  • emc易倍官网入口Cookie Policy
  • Privacy Policy
  • Accessibility

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen Canada website. To continue, please click Continue.

Continue

2026-07-09 16:13:58